Evergreen Therapeutics — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Evergreen Therapeutics is a private, Shenzhen and Princeton-based company that operates at the intersection of AI-driven drug discovery and regulatory consulting. Its core business model is providing fee-for-service solutions, including AI-powered R&D services, international regulatory strategy and submission (especially FDA), and business development/out-licensing support for pharmaceutical companies. The company's key differentiator is its team, which includes former FDA reviewers and international pharma executives, combined with its internally developed AI platform. It is positioned as a strategic enabler for the 'China innovation going global' trend.

AI / Machine Learning

Technology Platform

Proprietary AI platform for drug discovery and development, utilizing a 'dry-wet lab' combined approach. Capabilities include new molecule synthesis/optimization, pharmacology/toxicology prediction, indication expansion, and clinical phenotype analysis.

Opportunities

Capitalizing on the booming 'China-to-global' trend in biopharma, where Chinese innovators urgently need AI-driven R&D efficiency and expert FDA regulatory navigation to succeed internationally.

The growing adoption of AI across the drug discovery value chain presents a large and expanding market for its technology services.

Risk Factors

Heavy reliance on the financial health and global ambitions of the Chinese biotech sector, which can be cyclical.

Intensifying competition from other AI-CROs and regulatory consultancies.

Potential regulatory or geopolitical shifts that could hinder U.S.-China biopharma collaboration.

Competitive Landscape

Operates in a competitive space that includes pure-play AI drug discovery software firms, full-service global CROs with regulatory arms, and specialized regulatory consulting firms. Evergreen's key differentiator is the integration of a proprietary AI platform with a deep bench of former FDA regulators, offering a uniquely powerful combination for Chinese companies targeting the U.S. market.

More companies in AI / Machine Learning →More companies in United States →